AP570A - Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A. - Google Patents

Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A. Download PDF

Info

Publication number
AP570A
AP570A APAP/P/1993/000502A AP9300502A AP570A AP 570 A AP570 A AP 570A AP 9300502 A AP9300502 A AP 9300502A AP 570 A AP570 A AP 570A
Authority
AP
ARIPO
Prior art keywords
hepatitis
antigen
vaccine
hbsag
mpl
Prior art date
Application number
APAP/P/1993/000502A
Other languages
English (en)
Other versions
AP9300502A0 (en
Inventor
Nathalie Marie-Josephe Claude Garcon-Johnson
Pierre Hauser
Clothidle Thiriart
Pierre Voet
Original Assignee
Smithkline Beecham Biologicals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP570(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Application filed by Smithkline Beecham Biologicals S A filed Critical Smithkline Beecham Biologicals S A
Publication of AP9300502A0 publication Critical patent/AP9300502A0/xx
Application granted granted Critical
Publication of AP570A publication Critical patent/AP570A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
APAP/P/1993/000502A 1992-03-27 1993-03-25 Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A. AP570A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine

Publications (2)

Publication Number Publication Date
AP9300502A0 AP9300502A0 (en) 1993-04-30
AP570A true AP570A (en) 1996-11-29

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1993/000502A AP570A (en) 1992-03-27 1993-03-25 Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A.

Country Status (28)

Country Link
EP (1) EP0633784B2 (fr)
JP (1) JP3470719B2 (fr)
KR (1) KR100270134B1 (fr)
CN (1) CN1072963C (fr)
AP (1) AP570A (fr)
AT (1) ATE146678T1 (fr)
AU (4) AU3751693A (fr)
CA (1) CA2132833C (fr)
CZ (1) CZ283424B6 (fr)
DE (1) DE69306940T3 (fr)
DK (1) DK0633784T4 (fr)
ES (1) ES2098029T5 (fr)
FI (1) FI110843B (fr)
GR (1) GR3022174T3 (fr)
HK (1) HK1003218A1 (fr)
HU (1) HU221253B1 (fr)
IL (1) IL105161A (fr)
MA (1) MA22842A1 (fr)
MY (1) MY111880A (fr)
NO (1) NO309458B1 (fr)
NZ (1) NZ249868A (fr)
RU (1) RU2121849C1 (fr)
SA (1) SA93130573B1 (fr)
SG (1) SG48375A1 (fr)
SI (1) SI9300149B (fr)
SK (1) SK280160B6 (fr)
UA (1) UA44688C2 (fr)
WO (1) WO1993019780A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
DK0812593T4 (da) * 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ES2273482T3 (es) * 1998-03-09 2007-05-01 Glaxosmithkline Biologicals S.A. Composiciones de vacunas combinadas.
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
ATE357252T1 (de) 1998-10-16 2007-04-15 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ES2472441T3 (es) 2004-09-22 2014-07-01 Glaxosmithkline Biologicals S.A. Composición inmunog�nica para uso en vacunación contra estafilococos
PT1861120T (pt) 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
ES2420829T3 (es) 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AR058707A1 (es) 2005-12-22 2008-02-20 Glaxosmithkline Biolog Sa Vacuna, procedimiento para fabricarla y su uso
EA015271B1 (ru) 2006-01-27 2011-06-30 Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
CA2646539A1 (fr) 2006-03-23 2007-09-27 Novartis Ag Composes d'imidazoquinoxaline utilises en tant qu'immunomodulateurs
EP2004226A1 (fr) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Stockage de vaccins antigrippaux sans refrigeration
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP2054431B1 (fr) 2006-06-09 2011-08-31 Novartis AG Conformères d'adhésines bactériennes
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
KR20090057015A (ko) 2006-09-11 2009-06-03 노파르티스 아게 난을 사용하지 않는 인플루엔자 바이러스 백신의 제조
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
PL2185191T3 (pl) 2007-06-27 2013-02-28 Novartis Ag Szczepionki przeciwko grypie o małej zawartości dodatków
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CA2710480A1 (fr) 2007-12-24 2009-07-02 Novartis Ag Dosages pour vaccins adsorbes contre la grippe
AU2010220824A1 (en) 2009-03-05 2011-10-20 Jenny Colleen Mccloskey Treatment of infection
WO2011008974A2 (fr) 2009-07-15 2011-01-20 Novartis Ag Compositions à base de protéine f du vrs et procédés de fabrication associés
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CA2819416C (fr) 2010-12-02 2019-04-30 Bionor Immuno As Conception d'echafaudage peptidique
US9493514B2 (en) 2011-01-06 2016-11-15 Bionor Immuno As Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
HUE043879T2 (hu) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa RSV-immunizálási rend
DK3275892T3 (da) 2011-05-13 2020-04-06 Glaxosmithkline Biologicals Sa Præfusions-rsv-f-antigener
MX2014014683A (es) 2012-06-06 2015-02-24 Bionor Immuno As Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
WO2016207853A2 (fr) 2015-06-26 2016-12-29 Seqirus UK Limited Vaccins contre la grippe à correspondance antigénique
EP4103587A1 (fr) 2020-02-14 2022-12-21 Immunor AS Vaccin contre le coronavirus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175261A2 (fr) * 1984-09-12 1986-03-26 Chiron Corporation Immunogènes à base de particule hybride
GB2220211A (en) * 1988-06-29 1990-01-04 Ribi Immunochem Research Inc Modified lipopolysaccharides
WO1991016926A1 (fr) * 1990-05-07 1991-11-14 North American Vaccine, Inc. Compositions de vaccination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2012739T5 (es) * 1987-11-18 2001-12-01 Chiron Corp Diagnosticos para nanbv.
WO1989012641A1 (fr) * 1988-06-17 1989-12-28 Genelabs Incorporated Agent viral de l'hepatite non-a/non-b transmis par voie enterique
ATE159031T1 (de) * 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
JP3156200B2 (ja) * 1989-09-15 2001-04-16 国立予防衛生研究所長 新規のｈｃｖ分離株
WO1992011291A1 (fr) * 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) VACCINS A BASE DE l'ANTIGENE D'ENVELOPPE DU VIRUS DE L'HEPATITE B

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175261A2 (fr) * 1984-09-12 1986-03-26 Chiron Corporation Immunogènes à base de particule hybride
GB2220211A (en) * 1988-06-29 1990-01-04 Ribi Immunochem Research Inc Modified lipopolysaccharides
WO1991016926A1 (fr) * 1990-05-07 1991-11-14 North American Vaccine, Inc. Compositions de vaccination

Also Published As

Publication number Publication date
HU9402758D0 (en) 1994-12-28
DE69306940T2 (de) 1997-06-26
MY111880A (en) 2001-02-28
ES2098029T3 (es) 1997-04-16
AU1000802A (en) 2002-02-21
DK0633784T3 (da) 1997-01-20
RU94042386A (ru) 1996-08-20
IL105161A (en) 1998-08-16
NO943571L (no) 1994-11-14
IL105161A0 (en) 1993-07-08
DE69306940D1 (de) 1997-02-06
NO309458B1 (no) 2001-02-05
KR100270134B1 (ko) 2000-10-16
DK0633784T4 (da) 2001-12-31
NO943571D0 (no) 1994-09-26
HUT69931A (en) 1995-09-28
SK280160B6 (sk) 1999-09-10
AU3751693A (en) 1993-11-08
ES2098029T5 (es) 2002-03-16
CZ235594A3 (en) 1995-02-15
AU3397499A (en) 1999-08-19
SI9300149B (sl) 2003-02-28
WO1993019780A1 (fr) 1993-10-14
DE69306940T3 (de) 2002-09-19
AU767755B2 (en) 2003-11-20
AP9300502A0 (en) 1993-04-30
EP0633784A1 (fr) 1995-01-18
SI9300149A (en) 1993-12-31
HK1003218A1 (en) 1998-10-16
AU6445796A (en) 1996-11-07
NZ249868A (en) 1997-03-24
JPH07505372A (ja) 1995-06-15
SA93130573B1 (ar) 2004-08-31
CN1085805A (zh) 1994-04-27
JP3470719B2 (ja) 2003-11-25
CA2132833C (fr) 2007-03-06
FI110843B (fi) 2003-04-15
GR3022174T3 (en) 1997-03-31
CZ283424B6 (cs) 1998-04-15
SG48375A1 (en) 1998-04-17
EP0633784B2 (fr) 2001-10-17
CN1072963C (zh) 2001-10-17
ATE146678T1 (de) 1997-01-15
KR950700757A (ko) 1995-02-20
FI944442A (fi) 1994-09-26
HU221253B1 (en) 2002-09-28
SK115294A3 (en) 1995-06-07
CA2132833A1 (fr) 1993-10-14
UA44688C2 (uk) 2002-03-15
EP0633784B1 (fr) 1996-12-27
MA22842A1 (fr) 1993-10-01
FI944442A0 (fi) 1994-09-26
RU2121849C1 (ru) 1998-11-20

Similar Documents

Publication Publication Date Title
AP570A (en) Hepatitis vaccines containing 3-0-deacylated monophoshory lipid A.
AP766A (en) A vaccine based on hepatitis B antigen.
AP515A (en) "Vaccine compositions".
US6893644B2 (en) Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A
US6488934B1 (en) Hepatitis B vaccine